Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?
Elena Guillen, Gaston J Pineiro, Ignacio Revuelta...
https://pubmed.ncbi.nlm.nih.gov/32198834/Actively Recruiting
Led by Helio Tedesco Silva Junior · Updated on 2024-11-08
500
Participants Needed
1
Research Sites
121 weeks
Total Duration
COVID-19 is a highly contagious viral illness caused by the SARS-CoV-2 coronavirus, with main symptoms including fever and respiratory problems. Patients with pre-existing conditions like diabetes, hypertension, heart disease, lung diseases, chronic kidney disease, and weakened immune systems may experience worse outcomes. Kidney transplant recipients use immunosuppressive drugs to prevent organ rejection, which may change how COVID-19 affects them. Currently, limited information exists about COVID-19 outcomes in kidney transplant patients, so this study aims to detail their clinical and laboratory features and outcomes in a national multicenter group. The study observes kidney transplant recipients of any follow-up period who test positive for COVID-19 through viral load, antigen, or antibody tests. It includes both outpatients and hospitalized patients across all ages, including adults and children. The study does not involve treatments but collects data to understand the conditions impact on this population. Participants will have their clinical data collected regarding the need for mechanical ventilation, dialysis, ICU admission, and outcomes such as death or graft loss up to three months after COVID-19 resolution. Hospitalization duration is also tracked until discharge. The study follows patients for up to three months after recovery to monitor health outcomes and organ function.
CONDITIONS
SARS-COV-2 Infection in Kidney Transplant Recipients: a Brazilian Multicenter Study
H
Helio Tedesco
M
Monica Nakamura
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Helio Tedesco Silva Junior
Lead Sponsor
Hospital do Rim e Hipertensão
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) for confirmation of eligibility including COVID-19 test results
Duration - Up to 1 week
Participants undergo diagnostic testing for COVID-19 to confirm infection status.
1 to 2 visits depending on testing method
Duration - Until hospital discharge or clinical resolution, approximately 1 month
Participants are observed during outpatient or hospital management of COVID-19, including assessments of clinical and laboratory conditions.
Regular visits or assessments during outpatient or hospital care
Duration - Up to 3 months after resolution
Participants are followed for up to 3 months after resolution of COVID-19 to evaluate outcomes such as death and graft loss.
Periodic follow-up visits or assessments for up to 3 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Elena Guillen, Gaston J Pineiro, Ignacio Revuelta...
https://pubmed.ncbi.nlm.nih.gov/32198834/Wei-Jie Guan, Zheng-Yi Ni, Yu Hu...
https://pubmed.ncbi.nlm.nih.gov/32109013/P Conti, G Ronconi, A Caraffa...
https://pubmed.ncbi.nlm.nih.gov/32171193/Lan Zhu, Xizhen Xu, Ke Ma...
https://pubmed.ncbi.nlm.nih.gov/32181990/Luis Gustavo Modelli de Andrade, Tainá Veras de Sandes-Freitas, Lúcio R Requião-Moura...
https://pubmed.ncbi.nlm.nih.gov/34416075/Wenhua Liang, Weijie Guan, Ruchong Chen...
https://pubmed.ncbi.nlm.nih.gov/32066541/Lorenzo D'Antiga
https://pubmed.ncbi.nlm.nih.gov/32196933/Helio Tedesco Silva Junior
Lead Sponsor
Hospital do Rim e Hipertensão
Collaborating Sponsor